Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alumis Inc. (ALMS), Larimar Therapeutics (LRMR) and ...

Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS), Larimar Therapeutics (LRMR) and Eli Lilly & Co (LLY)

Citi analyst Samantha Semenkow reiterated a Buy rating on Larimar Therapeutics today and set a price target of $14.00. Semenkow covers the Healthca...

Citi Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

Larimar Therapeutics ( ($LRMR) ) has issued an update. On March 9, 2026, Larimar Therapeutics posted an updated corporate presentation outlining pr...

Current Quarter	$-0.53	Next Quarter	$-0.49
Current Year	$-1.93	Next Year	$-1.86
QoQ Growth	+7.5%	YoY Growth	+3.6%
3Y EPS CAGR	+23.5%	Target Price	$16.70
Consensus	Buy	Upside	+226.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LRMR	$5.12	+1.49%	1.02M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LRMR	$5.12	+1.5%	1.02M
3
4
5
6

LRMR

LRMR

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Larimar Therapeutics Inc. Data in Excel

Get Larimar Therapeutics Inc. Data in Excel